Comparing Veracyte (NASDAQ:VCYT) and Akumin (NASDAQ:AKUMQ)

Veracyte (NASDAQ:VCYTGet Free Report) and Akumin (NASDAQ:AKUMQGet Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation.

Valuation & Earnings

This table compares Veracyte and Akumin’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Veracyte $296.54 million 6.53 -$36.56 million ($0.69) -38.43
Akumin $749.63 million 0.05 -$156.76 million ($2.82) -0.13

Veracyte has higher earnings, but lower revenue than Akumin. Veracyte is trading at a lower price-to-earnings ratio than Akumin, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Veracyte and Akumin, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veracyte 1 0 4 0 2.60
Akumin 0 0 0 0 N/A

Veracyte presently has a consensus target price of $29.50, indicating a potential upside of 11.24%. Given Veracyte’s higher probable upside, research analysts plainly believe Veracyte is more favorable than Akumin.

Profitability

This table compares Veracyte and Akumin’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Veracyte -14.56% -2.09% -1.95%
Akumin -34.67% -1,249.92% -8.42%

Risk & Volatility

Veracyte has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500. Comparatively, Akumin has a beta of -1.02, meaning that its stock price is 202% less volatile than the S&P 500.

Institutional and Insider Ownership

36.1% of Akumin shares are held by institutional investors. 2.6% of Veracyte shares are held by insiders. Comparatively, 20.5% of Akumin shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Veracyte beats Akumin on 9 of the 13 factors compared between the two stocks.

About Veracyte

(Get Free Report)

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

About Akumin

(Get Free Report)

Akumin Inc. provides outpatient diagnostic imaging services in the United States. It operates in two segments, Radiology and Oncology. The company offers various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other diagnostic and interventional radiology procedures through owned and/or operated imaging locations. It provides outpatient radiology, and oncology services and solutions to hospitals and health systems across 48 states. Akumin Inc. was founded in 2015 and is headquartered in Plantation, Florida. On October 22, 2023, Akumin Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.

Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.